Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of CAD 109.72 million. The enterprise value is 153.53 million.

Market Cap	109.72M
Enterprise Value	153.53M

Important Dates

The next estimated earnings date is Friday, July 18, 2025.

Earnings Date	Jul 18, 2025
Ex-Dividend Date	n/a

Share Statistics

Cannara Biotech has 91.43 million shares outstanding. The number of shares has increased by 1.66% in one year.

Current Share Class	91.43M
Shares Outstanding	91.43M
Shares Change (YoY)	+1.66%
Shares Change (QoQ)	+0.74%
Owned by Insiders (%)	2.34%
Owned by Institutions (%)	0.13%
Float	44.71M

Valuation Ratios

The trailing PE ratio is 8.64.

PE Ratio	8.64
Forward PE	n/a
PS Ratio	1.17
PB Ratio	1.16
P/TBV Ratio	1.16
P/FCF Ratio	24.20
P/OCF Ratio	10.16
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 6.80, with an EV/FCF ratio of 33.86.

EV / Earnings	11.46
EV / Sales	1.63
EV / EBITDA	6.80
EV / EBIT	9.53
EV / FCF	33.86

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.52.

Current Ratio	2.35
Quick Ratio	0.64
Debt / Equity	0.52
Debt / EBITDA	2.16
Debt / FCF	10.78
Interest Coverage	3.55

Financial Efficiency

Return on equity (ROE) is 15.44% and return on invested capital (ROIC) is 7.41%.

Return on Equity (ROE)	15.44%
Return on Assets (ROA)	6.55%
Return on Invested Capital (ROIC)	7.41%
Return on Capital Employed (ROCE)	12.45%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.61
Inventory Turnover	1.33

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +62.16% in the last 52 weeks. The beta is 0.23, so Cannara Biotech's price volatility has been lower than the market average.

Beta (5Y)	0.23
52-Week Price Change	+62.16%
50-Day Moving Average	1.29
200-Day Moving Average	0.97
Relative Strength Index (RSI)	39.41
Average Volume (20 Days)	27,070

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of CAD 94.07 million and earned 13.40 million in profits. Earnings per share was 0.14.

Revenue	94.07M
Gross Profit	39.38M
Operating Income	16.10M
Pretax Income	13.59M
Net Income	13.40M
EBITDA	22.29M
EBIT	16.10M
Earnings Per Share (EPS)	0.14

Full Income Statement

Balance Sheet

The company has 5.06 million in cash and 48.86 million in debt, giving a net cash position of -43.81 million or -0.48 per share.

Cash & Cash Equivalents	5.06M
Total Debt	48.86M
Net Cash	-43.81M
Net Cash Per Share	-0.48
Equity (Book Value)	94.19M
Book Value Per Share	1.03
Working Capital	43.16M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 10.80 million and capital expenditures -6.26 million, giving a free cash flow of 4.53 million.

Operating Cash Flow	10.80M
Capital Expenditures	-6.26M
Free Cash Flow	4.53M
FCF Per Share	0.05

Full Cash Flow Statement

Margins

Gross margin is 41.86%, with operating and profit margins of 17.12% and 14.24%.

Gross Margin	41.86%
Operating Margin	17.12%
Pretax Margin	14.44%
Profit Margin	14.24%
EBITDA Margin	23.70%
EBIT Margin	17.12%
FCF Margin	4.82%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.66%
Shareholder Yield	n/a
Earnings Yield	12.21%
FCF Yield	4.13%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 1.8. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.8
Piotroski F-Score	n/a